(Q46713964)

24 December 2017

title

Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. (English)

1 reference

24 December 2017

author name string

G Williams

1

1 reference

24 December 2017

J A Ball

2

1 reference

24 December 2017

J M Burrin

3

1 reference

24 December 2017

G F Joplin

4

1 reference

24 December 2017

S R Bloom

5

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 1986

1 reference

24 December 2017

published in

The Lancet

1 reference

24 December 2017

volume

2

1 reference

24 December 2017

issue

8510

1 reference

24 December 2017

page(s)

774-778

1 reference

24 December 2017

Long-term treatment of acromegaly with bromocriptine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Bromocriptine treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Long term treatment of acromegaly with a long acting analogue of somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Interstitial pituitary irradiation with 90Y for the treatment of acromegaly. A reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Alpha particles versus conventional radiotherapy to the pituitary region: a comparison of risk-benefit.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Conventional Supervoltage Irradiation Is an Effective Treatment for Acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Growth hormone release inhibiting hormone in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Effects of Somatostatin on Gastrointestinal Propagation and Absorption of Oral Glucose in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

Overview of the association between insulin and atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2886%2990300-4

7 January 2021

10.1016/S0140-6736(86)90300-4

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

2876235

1 reference

24 December 2017